Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial.
Clin Trials., Nov (2012)
Infrared thermography of cutaneous melanoma metastases.
J. Surg. Res., Sep (2012)
Research incentive program for clinical surgical faculty associated with increases in research productivity.
J. Thorac. Cardiovasc. Surg., Nov;144(5):1003-9 (2012)
Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.
Melanoma Res., Aug;22(4):302-9 (2012)
Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.
Int. J. Dermatol., Apr;51(4):420-6 (2012)
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Cancer Res., Mar;72(5):1070-80 (2012)
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
J. Immunother., Jan;35(1):78-88 (2012)
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.
Clin. Cancer Res., Dec;17(23):7440-50 (2011)
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Clin. Cancer Res., Jan;18(1):256-62 (2012)
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
Cancer J., 17(5):343-50 (2011 Sep-Oct)
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Clin Trials., Oct;8(5):591-600 (2011)
Surgical resection for bulky or recurrent axillary metastatic melanoma.
J Surg Oncol., Jan;105(1):21-5 (2012)
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
J. Clin. Oncol., Jul;29(21):2924-32 (2011)
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res., Aug;21(4):274-84 (2011)
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
Clin. Cancer Res., May;17(10):3064-76 (2011)
VEGFR-2 expression in human melanoma: revised assessment.
Int. J. Cancer., Dec;129(12):2807-15 (2011)
Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera.
Ann. Surg., Apr;253(4):774-8 (2011)
Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.
J Transl Med., 9:26 (2011)
Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers.
Arch Dermatol., Feb;147(2):211-5 (2011)
Regional control and morbidity after superficial groin dissection in melanoma.
Ann. Surg. Oncol., May;18(5):1453-9 (2011)
Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
J. Immunother., 33(9):965-74 (2010 Nov-Dec)
Evaluation of molecular markers of mesenchymal phenotype in melanoma.
Melanoma Res., Dec;20(6):485-95 (2010)
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.
J Transl Med., 8:79 (2010)
Interface of signal transduction inhibition and immunotherapy in melanoma.
Cancer J., 16(4):360-6 (2010 Jul-Aug)
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Clin Trials., Aug;7(4):312-21 (2010)
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
J. Immunother., 33(6):630-8 (2010 Jul-Aug)
A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage.
Ann. Surg. Oncol., Sep;17(9):2465-70 (2010)
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Clin. Cancer Res., Nov;15(22):7036-44 (2009)
Resident research forums stimulate novel research within general surgical training programs.
J Surg Educ., 66(3):146-51 (2009 May-Jun)
Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera.
J Surg Oncol., Nov;100(6):481-3 (2009)
Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis.
J. Cutan. Pathol., Jan;37(1):94-8 (2010)
Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis.
J. Clin. Oncol., Aug;27(23):3772-7 (2009)
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
J Transl Med., 7:45 (2009)
Neonatal congenital malignant melanoma with lymph node metastasis.
J. Clin. Oncol., Jun;27(16):2726-8 (2009)
Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis.
J. Cutan. Pathol., Apr;36(4):425-32 (2009)
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.
Vaccine., Mar;27(11):1764-70 (2009)
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
J Transl Med., 6:81 (2008)
The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines.
BMC Cancer., 8:360 (2008)
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
Ann. Surg. Oncol., Dec;15(12):3538-49 (2008)
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.
Cancer Immunol. Immunother., Jun;58(6):867-76 (2009)
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
J. Clin. Oncol., Oct;26(30):4973-80 (2008)
Skin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to go.
Ann. Surg. Oncol., Nov;15(11):3028-35 (2008)
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
Cancer Res., Jun;68(11):4392-7 (2008)
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
J. Immunother., May;31(4):420-30 (2008)
The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
J. Immunother., Jan;31(1):7-17 (2008)
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Clin. Cancer Res., Nov;13(21):6386-95 (2007)
Extensive neurocristic hamartoma with skeletal muscle involvement.
J. Cutan. Pathol., Aug;34(8):634-9 (2007)
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Adv. Immunol., 90:243-95 (2006)
Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.
J. Biol. Chem., Jul;281(27):18763-73 (2006)
Peptide and dendritic cell vaccines.
Clin. Cancer Res., Apr;12(7 Pt 2):2342s-2345s (2006)
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Clin. Cancer Res., Apr;12(7 Pt 2):2291s-2296s (2006)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.
J Transl Med., Oct;3:39 (2005)
Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients.
J. Clin. Oncol., Oct;23(28):7074-80 (2005)
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
J. Immunother., 28(4):412-9 (2005 Jul-Aug)
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
J. Immunol., Jun;174(11):6863-71 (2005)
Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.
Cancer Immunol. Immunother., Nov;54(11):1095-105 (2005)
Progress and controversies in developing cancer vaccines.
J Transl Med., Apr;3(1):18 (2005)
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
J. Immunol., Mar;174(5):3080-6 (2005)
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
J. Clin. Oncol., Nov;22(22):4474-85 (2004)
Competition among peptides in melanoma vaccines for binding to MHC molecules.
J. Immunother., 27(6):425-31 (2004 Nov-Dec)
CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.
Cancer Res., Nov;64(21):7697-701 (2004)
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members.
Cancer Immunol. Immunother., Apr;54(4):359-71 (2005)
Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.
J. Immunother., 27(5):380-8 (2004 Sep-Oct)
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
J. Biol. Chem., Aug;279(32):33168-76 (2004)
Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.
J. Immunother., 27(3):177-83 (2004 May-Jun)
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res., Feb;64(3):1157-63 (2004)
Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines.
Clin. Cancer Res., Jan;10(1 Pt 1):101-12 (2004)
Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes.
Immunol. Lett., Dec;90(2-3):131-5 (2003)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
J. Clin. Oncol., Nov;21(21):4016-26 (2003)
Complete spontaneous regression of pulmonary metastatic melanoma.
Dermatol Surg., Aug;24(8):915-9 (1998)
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
J. Immunol., Feb;160(3):1139-47 (1998)
Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
J. Immunother., Mar;21(2):85-94 (1998)
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
J. Immunol., Mar;160(5):2099-106 (1998)
Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy.
Ann. Surg., Jun;225(6):726-31; discussion 731-3 (1997)
Tumor antigens and tumor vaccines: peptides as immunogens.
Semin Surg Oncol., 12(6):446-53 (1996 Nov-Dec)
Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68.
Cancer Res., May;54(10):2731-7 (1994)
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.
Ann. Surg., Feb;219(2):120-30 (1994)
Malignant melanoma and the prognostic implications of pregnancy, oral contraceptives, and exogenous hormones.
Semin Surg Oncol., 9(3):228-31 (1993 May-Jun)
Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
J. Immunol., Apr;150(7):2955-63 (1993)
Multiple primary melanoma: incidence and risk factors in 283 patients.
Surgery., Mar;113(3):330-9 (1993)
The annual risk of melanoma progression. Implications for the concept of cure.
Cancer., Oct;70(7):1917-27 (1992)